Corcept Therapeutics Inc CORT
We take great care to ensure that the data presented and summarized in this overview for CORCEPT THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CORT
View all-
Black Rock Inc. New York, NY16.5MShares$1.22 Billion0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.68MShares$712 Million0.01% of portfolio
-
Ingalls & Snyder LLC New York, NY7.72MShares$568 Million20.11% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny6.27MShares$461 Million0.65% of portfolio
-
Parallel Advisors, LLC3.87MShares$285 Million5.83% of portfolio
-
State Street Corp Boston, MA2.97MShares$218 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.09MShares$153 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA1.92MShares$141 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.61MShares$119 Million0.01% of portfolio
-
Clearbridge Investments, LLC New York, NY1.17MShares$85.9 Million0.07% of portfolio
Latest Institutional Activity in CORT
Top Purchases
Top Sells
About CORT
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Insider Transactions at CORT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 11
2025
|
Daniel N Swisher Jr |
SELL
Open market or private sale
|
Direct |
2,200
-100.0%
|
$158,400
$72.3 P/Share
|
|
Aug 11
2025
|
Daniel N Swisher Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+50.0%
|
$30,800
$14.08 P/Share
|
|
Aug 08
2025
|
William Guyer Chief Development Officer |
SELL
Open market or private sale
|
Direct |
35,007
-86.45%
|
$2,485,497
$71.77 P/Share
|
|
Aug 08
2025
|
William Guyer Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,007
+46.37%
|
$735,147
$21.65 P/Share
|
|
Aug 05
2025
|
William Guyer Chief Development Officer |
SELL
Open market or private sale
|
Direct |
14
-0.25%
|
$994
$71.77 P/Share
|
|
Aug 05
2025
|
William Guyer Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14
+0.25%
|
$294
$21.65 P/Share
|
|
Aug 01
2025
|
Joseph K Belanoff Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.46%
|
$2,720,000
$68.78 P/Share
|
|
Aug 01
2025
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
35,007
-40.05%
|
$2,380,476
$68.58 P/Share
|
|
Aug 01
2025
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
35,007
+45.06%
|
$175,035
$5.05 P/Share
|
|
Aug 01
2025
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
5,823
-36.65%
|
$390,141
$67.51 P/Share
|
|
Aug 01
2025
|
Joseph Douglas Lyon |
BUY
Exercise of conversion of derivative security
|
Direct |
5,823
+26.82%
|
$75,699
$13.56 P/Share
|
|
Jul 18
2025
|
William Guyer Chief Development Officer |
SELL
Open market or private sale
|
Direct |
500
-8.35%
|
$36,500
$73.44 P/Share
|
|
Jul 18
2025
|
William Guyer Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+7.71%
|
$10,500
$21.65 P/Share
|
|
Jul 18
2025
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
200
-1.95%
|
$14,600
$73.4 P/Share
|
|
Jul 18
2025
|
Joseph Douglas Lyon |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.91%
|
$2,600
$13.56 P/Share
|
|
Jul 18
2025
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
473
-2.6%
|
$34,529
$73.44 P/Share
|
|
Jul 18
2025
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
473
+2.54%
|
$2,365
$5.05 P/Share
|
|
Jul 17
2025
|
William Guyer Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,379
-44.38%
|
$319,667
$73.48 P/Share
|
|
Jul 17
2025
|
William Guyer Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,379
+30.74%
|
$91,959
$21.65 P/Share
|
|
Jul 17
2025
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
3,877
-27.81%
|
$283,021
$73.48 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 34.3K shares |
|---|---|
| Bona fide gift | 4.64K shares |
| Exercise of conversion of derivative security | 1.12M shares |
| Other acquisition or disposition | 207K shares |
| Open market or private sale | 895K shares |
|---|---|
| Payment of exercise price or tax liability | 196K shares |
| Bona fide gift | 230K shares |
| Other acquisition or disposition | 7.25K shares |